IRONWOOD PHARMACEUTICALS, INC. Unrealized Gain (Loss) on Derivatives
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Unrealized Gain (Loss) on Derivatives of -$8.70 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2019-02-25
- IRONWOOD PHARMACEUTICALS, INC. unrealized gain (loss) on derivatives for fiscal 2018 was -$8.70M.
- IRONWOOD PHARMACEUTICALS, INC. unrealized gain (loss) on derivatives for fiscal 2009 was $600.00K.
| Period end | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|
| 2018-12-31 | -$8.70M 10-K · filed 2019-02-25 |
| 2009-12-31 | $600.00K 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |